Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05039723 · ClinicalTrials.gov registry record · Phase 4

Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational

A Phase 4 study of Photoaging, sponsored by Main Line Center for Laser Surgery.

Completed
Registry status
Phase 4
Development phase
22
Enrollment target
1
Study location

NCT05039723 is a Phase 4 study of Photoaging that has completed, run by Main Line Center for Laser Surgery. The registered enrollment target is 22 participants, below the 30-participant average among 14 other Photoaging trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05039723, a Phase 4 study of Photoaging, has completed, sponsored by Main Line Center for Laser Surgery.

COMPLETED
Registry status
Phase 4
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the improvement in signs of photoaging and subject satisfaction after combination, global facial and/or neck treatment with IncobotulinumA (Xeomin), HA (Belotero) and/or calcium hydroxyapatite (Radiesse+, Radiesse Classic). All products will be used on-label FDA-cleared indications.

Conditions Studied

Interventions

  • DRUG Radiesse, Xeomin, Belotero

Study Locations (1)

Pennsylvania

  • Main Line Center for Laser Surgery - Ardmore

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2021-09-01
Est. Completion 2022-07-01
Phase Phase 4

What the Registry Record Tells You About NCT05039723

The ClinicalTrials.gov registry entry for NCT05039723 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 30-participant average among 14 other Photoaging trials with a reported enrollment target (27% lower). The listed sponsor is Main Line Center for Laser Surgery, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Photoaging appearing as the primary indexed condition, and to 1 intervention - of which Radiesse, Xeomin, Belotero is the first listed.

NCT05039723 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05039723 about?

NCT05039723 is a clinical study titled "Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational". The purpose of this study is to determine the improvement in signs of photoaging and subject satisfaction after combination, global facial and/or neck treatment with IncobotulinumA (Xeomin), HA (Belotero) and/or calcium hydroxyapatite (Radiesse+, Radiesse Classic). All products will be used on-label...

What is the current status of trial NCT05039723?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2021-09-01. Estimated completion is 2022-07-01.

What conditions does trial NCT05039723 study?

This clinical trial studies the following conditions: Photoaging.

What interventions are being tested in trial NCT05039723?

The interventions under investigation include: Radiesse, Xeomin, Belotero (DRUG).

Who is sponsoring clinical trial NCT05039723?

This trial is sponsored by Main Line Center for Laser Surgery, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05039723 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Photoaging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.